证券代码：002907 证券简称：华森制药 公告编号：2025-058 重庆华森制药股份有限公司 关于公司药品生产许可证变更的公告 | 企 | 业 | | 名 | 称 ：重庆华森制药股份有限公司 | | --- | --- | --- | --- | --- | | 许 | 可 | 证 | 编 | 号 ：渝 20150018 | | 社 | 会 信 | | 用 代 | 码 ：915002262038944463 | | 分 | | 类 | | 码 ：AhzyBhzChDh | | 注 | 册 | | 地 | 址 ：重庆市荣昌区工业园区 | | 法 | 定 | 代 | 表 | 人 ：游洪涛 | | 企 | 业 | 负 | 责 | 人 ：游洪涛 | | 质 | 量 | 负 | 责 | 人 ：邓林 | | 质 | 量 | 受 | 权 | 人 ：王茜 | | 生 | 产 | 负 | 责 | 人 ：周帮建 | | 有 | 效 | | 期 | 至 ：2030 年 06 月 29 日 | 生产地址和生产范围 ：重庆市荣昌区工业园区：颗粒剂，粉针剂，散剂，冻干 粉针剂，原料药，软胶囊剂，小容量注射剂，硬胶囊 剂，片剂，吸入溶 ...

Policy Developments - The National Healthcare Security Administration (NHSA) held the first session of a series of discussions on supporting innovative drugs and medical devices, with over 20 representatives from pharmaceutical companies, research institutions, and medical organizations participating. The meeting emphasized the NHSA's commitment to supporting true innovation and the importance of a comprehensive value assessment for innovative products to enhance healthcare resource utilization and better serve public health [2]. Drug and Device Approvals - Shanghai Pharmaceuticals announced that its subsidiary's tranexamic acid injection has received approval from the National Medical Products Administration (NMPA) after passing the consistency evaluation for generic drugs. This drug is primarily used for various bleeding conditions caused by primary fibrinolysis [4]. - Huason Pharmaceutical received re-registration approval for three drugs from the Chongqing Drug Administration, including Ganqi Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets [5]. - Huiren Pharmaceutical's subsidiary received approval for the listing of methochlorpromazine hydrochloride raw materials, which are used for preventing postoperative nausea and vomiting, as well as treating nausea related to migraines and radiation therapy. Additionally, the subsidiary received a medical device registration certificate for a sterile, single-use syringe [6]. Capital Market Activities - ST Jingfeng announced the sale of a 51% stake in its subsidiary Jiangxi Yanhua Pharmaceutical to Jiangxi Shaoyang Pharmaceutical for a price of 142,500 yuan. Following this transaction, Jiangxi Yanhua will no longer be included in the company's consolidated financial statements [8]. Industry Events - Sichuan University West China Hospital successfully completed the first implanted brain-machine interface surgery in Western China for a patient with spinal cord injury, allowing the patient to control a mechanical hand using brain signals [10][11]. - Samsung Medical's subsidiary signed a procurement framework contract in Brazil worth approximately 341 million yuan, which represents 2.33% of the company's audited revenue for 2024 [12].

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

（二）六味安神胶囊 | | | | 药 | 品 | | 通 | 用 | 名 | 称：甘桔冰梅片 | | --- | --- | --- | --- | --- | --- | --- | | 受 | | | 理 | | | 号：CYZZ2418814 渝 | | 通 | | 知 | 书 | | 编 | 号：2025R037108 | | 剂 | | | | | | 型：片剂 | | 规 | | | | | | 格：糖衣片，片心重 0.2g | | 注 | | 册 | | 分 | | 类：中药 | | 药 | 品 | 注 | 册 | 标 | 准 编 | 号：《中国药典》2020 年版一部 | | 药 | 品 | | 批 | 准 | 文 | 号：国药准字 Z20026258 | | 药 | | 品 | 有 | | 效 | 期：24 个月 | | | | 药 品 批 准 文 号 | | | | 有 效 期：至 2030 年 04 月 28 日 | | 审 | | 批 | | 结 | | 论：经审查，本品符合《药品注册管理办法》的有关 规定，同意再注册。 | 证券代码：002907 证券简称：华森制药 公告编号：20 ...

1. 艾罗能源(688717.SH)：公司及多名董监高因个人资金需求，计划在15个交易日后3个月内通过集中竞价或大宗交易方式减持股 份，减持数量不超过公司总股本的0.78%。 2. 奥普光电(002338.SZ)：控股股东长春光机所计划在15个交易日后90日内，以集中竞价方式减持公司股份不超过240万股，占公 司总股本的1%。 3. 铂科新材(300811.SZ)：股东铂科天成及其一致行动人合计减持1.01%股份，减持计划实施完毕，同时股东梅建军合计减持8134 股，占总股本的0.0476%。 4. 博迁新材(605376.SH)：股东新辉投资计划在15个交易日后3个月内通过大宗交易减持公司股份不超过261.6万股，占公司总股本 的1%。 5. 博盈特焊(301468.SZ)：股东前海股权基金和中原前海基金减持计划实施完成，合计减持394.48万股，占公司总股本的2.99%。 6. 测绘股份(300826.SZ)：高级管理人员刘键计划在15个交易日后3个月内通过集中竞价方式减持公司股份不超过5万股，占公司总 股本的0.03%。 13. 红宝丽(002165.SZ)：控股股东宝源投资及实际控制人芮敬功计划在15 ...

| 合 | 计 | 4,175,800 | | 1 | | | --- | --- | --- | --- | --- | --- | | 本次权益变动方式 | | 通过证券交易所的集中交易 | | □ | | | （可多选） | | 通过证券交易所的大宗交易 | | ☑ | | | | | 其他 | | □（请注明） | | | | | 3．本次变动前后，成都地建及其一致行动人拥有上市公司权益的股份情况 | | | | | 股东 | | 本次变动前持有股份 | | 本次变动后持有股份 | | | 名称 | 股份性质 | 股数(股) | 占总股本 | 股数(股) | 占总股本比 | | | | | 比例(%) | | 例(%) | | 合计持有股份 | | 169,065,675 | 40.49 | 164,889,875 | 39.49 | | 成都 地建 | 其中：无限售 条件股份 | 169,065,675 | 40.49 | 164,889,875 | 39.49 | | 有限售 | | 0 | 0 | 0 | 0 | | 条件股份 | | | | | | | 游 | 合计持有股份 | 72,422, ...

Core Insights - The article highlights the journey of Huason Pharmaceutical, founded by You Hongtao, who transitioned from a stable academic career to entrepreneurship driven by a desire to produce affordable medicine for the public [2][3][4] - The company is focusing on original research and innovation, particularly in traditional Chinese medicine and innovative drugs, targeting the global pharmaceutical market [2][6][10] Company Background - You Hongtao founded Huason Pharmaceutical in the 1990s, motivated by a personal experience witnessing a child unable to afford necessary medication [3] - The company has evolved over 28 years, now emphasizing original research and innovation to ensure long-term growth [2] Challenges Faced - The company faced significant challenges during its early years, including financial difficulties and the need for technological breakthroughs [4][5] - A notable incident involved You Hongtao struggling to collect overdue payments to pay employee bonuses, highlighting the harsh realities of entrepreneurship [4] Innovation Strategy - Huason Pharmaceutical has established a dedicated innovative drug division, focusing on oncology and autoimmune diseases, with a commitment to self-sufficiency in healthcare [6][7] - The company has built 22 production lines and a smart factory, allowing for stable cash flow and reinvestment into innovation [7] Research and Development - The company has developed 7 original innovative drugs and 1 modified innovative drug, targeting various cancers and immune-related diseases [9] - Huason has established a PROTAC technology platform and is advancing multiple innovative drug projects, with some already in clinical stages [9] Market Expansion - The company is expanding into the health and wellness sector, particularly through specialized medical foods, addressing the nutritional needs of patients [10][11] - Huason is also focusing on the aging population, developing products aimed at improving sleep, nutrition, and bone health [11] Internationalization Efforts - Huason Pharmaceutical is exporting traditional Chinese medicine to Southeast Asia and chemical drugs to Europe and the US, with several products already registered in Singapore [12] - The company’s production facility has received FDA certification, positioning it well for international market entry [12]

| 企 | | 业 | | 名 | 称 ：重庆华森制药股份有限公司 | | --- | --- | --- | --- | --- | --- | | 许 | 可 | | 证 | 编 | 号 ：渝 20150018 | | 社 | 会 | 信 | 用 | 代 | 码 ：915002262038944463 | | 分 | | | 类 | | 码 ：AhzyBhzChDh | | 注 | | 册 | | 地 | 址 ：重庆市荣昌区工业园区 | | 法 | 定 | | 代 | 表 | 人 ：游洪涛 | | 企 | 业 | | 负 | 责 | 人 ：游洪涛 | | 质 | 量 | | 负 | 责 | 人 ：邓林 | | 质 | 量 | | 受 | 权 | 人 ：王茜 | | 生 | 产 | | 负 | 责 | 人 ：周帮建 | | 有 | | 效 | | 期 | 至 ：2030 年 06 月 29 日 | | | | | | | 生产地址和生产范围 ：重庆市荣昌区工业园区：粉针剂，散剂，颗粒剂，软胶 | | | | | | | 囊剂，原料药，冻干粉针剂，小容量注射剂，片剂，硬 | | | | | | | 胶囊剂，吸 ...

Group 1: Company Overview and Performance - The company introduced its operational performance, product layout, market development, and production management while ensuring compliance with information disclosure regulations [2] - As of May 2025, the company has integrated its R&D pipeline with Chengdu Aorui Pharmaceutical Co., enhancing its small molecule innovative drug development capabilities [3] - The company has established multiple independent R&D platforms and has applied for 35 patents, including 17 PCT patents [3] Group 2: Innovative Drug Development - Currently, there are 7 proprietary Class 1 innovative drug projects under development, targeting various cancers and autoimmune diseases [3] - The lead project, ORIC-1940, is in clinical Phase Ia/Ib research and is expected to be the first Class 1 innovative drug for secondary hemophagocytic lymphohistiocytosis (HLH) in China [3] - The company plans to submit IND applications for two additional projects by the end of this year and the first quarter of next year [3] Group 3: Clinical Data and Future Prospects - Anticipated Phase Ib data for ORIC-1940 is expected next year, with the timeline dependent on patient enrollment speed [4] - ORIC-1940 offers a differentiated mechanism of action compared to existing therapies, potentially addressing the limitations of current HLH treatments [5] - The company is considering expanding ORIC-1940's indications to include primary HLH and other autoimmune diseases [6] Group 4: International Market Expansion - The company has achieved significant milestones in international markets, including passing the FDA's cGMP inspection in May 2023 [7] - Key traditional Chinese medicine products have received registration approvals for sale in Singapore, marking a critical milestone for the company's export strategy [7]

证券代码：002907 证券简称：华森制药 公告编号：2025-054 重庆华森制药股份有限公司 关于公司产品完成境内生产药品备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日从国家药品监督管 理局（以下简称"国家药监局"）网站查询获知公司产品苍耳子鼻炎胶囊完成境 内生产药品备案（延长药品有效期申请），并于国家药监局网站公示备案信息。 现将相关情况公告如下： 一、药品基本信息 （一）延长药品有效期申请 1.苍耳子鼻炎胶囊 药品通用名称 ： 苍耳子鼻炎胶囊 备案号 ： 渝备 2025021509 药品批准文号 / 原料药登记号 ：国药准字 Z20033142 上 市 许 可 持 有 人 ：重庆华森制药股份有限公司 上市许可持有人地址 ： 重庆市荣昌区工业园区 生产企业名称 ：重庆华森制药股份有限公司 生产企业地址 ： 重庆市荣昌区昌州街道板桥路 143 号 四、风险提示 备 案 内 容 ： 延长本品有效期由 18 个月变更为 24 个月 备 案 机 关 ：重庆市药品监督管理局 备 案 日 期 ：2025 ...